Endoscopic Ultrasound-guided Trans-esophageal Transmural Drainage of Mediastinal Pseudocysts: A Case Series
Journal of Gastrointestinal and Liver Diseases · 2023
DOI: 10.15403/jgld-4530 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastrointestinal and Liver Diseases, 2023. Verfasst von Surinder Singh Rana und 4 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Departement, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. drsurinderrana@yahoo.co.in. Hauptthemen laut MEDLINE: Pancreatic Pseudocyst, Pancreatitis, Acute Necrotizing. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background and Aims: Mediastinal pseudocysts (MP) are rare, and surgery is the conventional treatment modality. However, in the last decade, excellent outcomes have been reported with endoscopic transpapillary drainage. Endoscopic ultrasound (EUS) guided trans-esophageal transmural drainage of MP is a minimally invasive and effective non-surgical treatment modality, but the experience is limited. We aimed to report our experience of EUS-guided transmural drainage in 10 patients with MP‘s.
Methods
A retrospective analysis of patients with pancreatic fluid collections treated with EUS-guided transmural drainage over the last ten years was completed to to identify patients with MP‘s.
Results
Ten patients (8 males, with a mean age of 34.9±9.17 years) with MP treated with EUS-guided transesophageal transmural drainage were identified. Nine patients with MP had concurrent chronic pancreatitis, and only one had MP following acute necrotizing pancreatitis. The mean size of MP was 5.70±1.64 cm, and nine patients (90%) had concurrent abdominal pseudocyst. EUS-guided transesophageal transmural drainage was technically successful in all ten patients. Transmural plastic stents were placed in 9 patients, whereas one patient underwent single-time complete aspiration of the MP. There were no immediate or delayed procedure-related complications. All ten patients had a successful outcome, with the mean resolution time being 2.80±0.79 weeks. There has been no recurrence of PFC or symptoms in nine (90%) successfully treated patients over a mean follow-up period of 43.3 months.
Conclusions
EUS-guided trans-esophageal drainage of MP is safe with a high technical and clinical success rate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Gastroenterology Departement, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. drsurinderrana@yahoo.co.in.
- Gastroenterology Departement, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. drarupc@gmail.com.
- Gastroenterology Departement, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. Dayakrishna.jha@gmail.com.
- Gastroenterology Departement, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. pankdoct2@gmail.com.
- Surgical Gastroenterology Departement, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. rajsarakshi@gmail.com.
Zitieren
APA
Rana, S. S., Choudhary, A., Jha, D. K., Kumar, P., & Gupta, R. (2023). Endoscopic Ultrasound-guided Trans-esophageal Transmural Drainage of Mediastinal Pseudocysts: A Case Series. Journal of Gastrointestinal and Liver Diseases. https://doi.org/10.15403/jgld-4530
Vancouver
Rana SS, Choudhary A, Jha DK, Kumar P, Gupta R. Endoscopic Ultrasound-guided Trans-esophageal Transmural Drainage of Mediastinal Pseudocysts: A Case Series. Journal of Gastrointestinal and Liver Diseases. 2023. doi:10.15403/jgld-4530
BibTeX
@article{Rana2023,
author = {Rana, Surinder Singh and Choudhary, Arup and Jha, Daya Krishna and Kumar, Pankaj and Gupta, Rajesh},
title = {Endoscopic Ultrasound-guided Trans-esophageal Transmural Drainage of Mediastinal Pseudocysts: A Case Series},
journal = {Journal of Gastrointestinal and Liver Diseases},
year = {2023},
doi = {10.15403/jgld-4530}
}
EUVIMED